|
BioScreening - organic compounds for screening
07.10.2009 New Method Takes Aim At Aggressive Cancer Cells
A multi-institutional team of Boston-area researchers has discovered a chemical that works in mice to kill the rare but aggressive cells within breast cancers that have the ability to seed new tumors.
These cells, known as cancer stem cells, are thought to enable cancers to spread — and to reemerge after seemingly successful treatment. Although further […]
More bioscreening news...
22.10.2009 BioLeap Wins GlaxoSmithKline Contract to Design Novel Lead Compounds for Previously Intractable Targets for Important Unmet Medical Needs.
BioLeap and GSK have entered into an agreement whereby BioLeap will design novel
lead compounds for “difficult” drug targets. The targets (not disclosed) are
ones for which conventional approaches, like high throughput screening, have
failed to yield a viable chemical starting point. Typically these are in areas
of high unmet medical need.
BioLeap will use its computational fragment-based drug design
More bioscreening news...
22.10.2009 InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T™ Technology for production of recombinant proteins
Cologne, Germany, October 01, 2009 / b3c newswire / - CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes and the contract manufacturer InVivo BioTech Services GmbH announced today the signing of a strategic license agreement. This license enables InVivo to offer its customers the production of
More bioscreening news...
22.10.2009 KINAXO launches KinAffinity® services for efficient profiling of kinase inhibitors in cells or tissue
Martinsried, Germany, October 01, 2009 / b3c newswire / - KINAXO Biotechnologies GmbH announced today that it added KinAffinity® to its service portfolio. KinAffinity® provides invaluable information about a kinase inhibitor’s selectivity in a cell or tissue of interest. It simultaneously determines affinities for native kinases expressed within a cellular
More bioscreening news...
22.10.2009 Evotec Announces Research Agreement With Biogen Idec
HAMBURG, Germany and OXFORD, UK, Sept. 9, 2009 (GLOBE NEWSWIRE) — Evotec AG
(Frankfurt:EVT) (Nasdaq:EVTC), a leading provider in the discovery and
development of novel small molecule drugs, today announced that it has entered
into a research agreement with Biogen Idec (Nasdaq:BIIB), a leading
biopharmaceutical company headquartered in Cambridge, Mass., USA.
Evotec will use its expertise and technologies in protein
More bioscreening news...
22.10.2009 Ore Pharmaceuticals Announces Upcoming Publication of Research Study on ORE1001
Ore Pharmaceuticals Inc. (Nasdaq:ORXE), announced today the publication of an
article in the online version of the journal Inflammation Research titled,
“Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced
colitis in mice.”
This article discussed the efficacy of Ore`s lead drug candidate, ORE1001
(formerly GL1001), in the dextran sodium sulfate animal screening model for
inflammatory bowel disease drugs
More bioscreening news...
22.10.2009 Agilux Laboratories Hires New Associate Director to Lead In Vitro ADMET Services Division
- Adrian Sheldon, Ph.D., Positions Contract Research Organization for Growth -
WORCESTER, Mass.–(Business Wire)–
Agilux Laboratories, Inc., a Contract Research Organization (CRO) that provides
bioanalytical and in vitro Absorption Distribution Metabolism Excretion
Toxicology (ADMET) services for the biotechnology and pharmaceutical industries,
has appointed Dr. Adrian Sheldon as associate director of In Vitro ADMET
Services. In this role, Dr. Sheldon will build
More bioscreening news...
22.10.2009 Sirona Biochem Says SGLT Test Results Confirm Key ‘Breakthrough’
Sirona Biochem Corp. (TSX-V: SBM), an emerging biotech company focused on diabetes and obesity, says results of testing its unique SGLT inhibitor molecules demonstrate a key breakthrough milestone for Sirona Biochem.
Sirona Biochem CEO, Dr. Howard Verrico, said, “There are two vital steps in the early stage of drug testing: validation of concept i.e. a molecule
More bioscreening news...
22.10.2009 Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG Company gains access to proprietary antibody fragment technology particularly suited to treat eye diseases
HUENENBERG, Switzerland & ZURICH, Sep 13, 2009 (BUSINESS WIRE) — –Acquisition establishes sustainable platform for ongoing biologics development
–Deal builds on other recent transactions to expand breadth and depth of Alcon’s development opportunities in eye care in the long term
–ESBATech shareholders retain rights to non-ophthalmic technology and products
Alcon
More bioscreening news...
22.10.2009 Zelinsky Institute Inc. announced collaboration with ART-CHEM
Zelinsky Institute Inc. (Newark, DE, August 2009) - Zelinsky Institute Inc. expands its partnership and supplier network with the announcement of collaboration with one of the premier fine chemistry companies - ART-CHEM, which originated from Moscow, Russia, and has started its operations in Berlin, Germany, in 2005. ART-CHEM specializes in synthesis of highly diverse
More bioscreening news...
22.10.2009 Novel two-step chemical process makes cancer cells glow quickly, safely
WASHINGTON - Researchers at Massachusetts General Hospital have developed a two-step process that uses a chemical reaction to make live cancer cells light up quickly and safely.
This attains significance because scientists generally label cells with coloured or glowing chemicals to observe how basic cellular activities differ between healthy and cancerous cells, but existing techniques are
More bioscreening news...
22.10.2009 DiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant by the NIH to Discover Hypertension and Cystic Fibrosis (CF) Drugs
BIRMINGHAM, Ala.–(BUSINESS WIRE)–DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the
More bioscreening news...
22.10.2009 GENFIT identifies compounds which modulate clock genes for the treatment of cardiometabolic disease and CNS disorders
Lille (France), Cambridge (Massachusetts, United States), September 28, 2009 - GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces the successful identification of Hit compounds for an orphan nuclear receptor which plays a
More bioscreening news...
22.10.2009 Trophos launches the new generation of its fast plate imaging instrument, the Plate RUNNER HD
Marseille, FRANCE, 2009 September 29 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology, announced today the launch of the new generation of its fluorescence
More bioscreening news...
22.10.2009 AIDS Study Flushes Out Hidden Virus, Pointing to Possible Cure
Oct. 2 (Bloomberg) — Scientists, moving closer to a cure for AIDS, identified a way to find medicines that would help rid patients of the hardest-to-treat pockets of HIV.
Current anti-HIV drugs reduce the virus to undetectable levels without eradicating it. The virus survives by lying dormant in immune-system cells, where the medicines don’t reach them.
More bioscreening news...
22.10.2009 EPA seeks broad powers to regulate chemical industry
By RANDY LEE LOFTIS / The Dallas Morning News
rloftis@dallasnews.com The Obama administration announced Tuesday that it is seeking broad new powers to regulate toxic substances in commerce, products and the environment, including clear authority to ban unsafe chemicals.
Environmental Protection Agency Administrator Lisa Jackson laid out the administration’s principles for rewriting the nation’s
More bioscreening news...
22.10.2009 MALDI-Based Method May Reduce Cost of Rx-Screening Assays, Speed Drug Development
This story originally ran on Oct. 6.
By Tony Fong
Researchers from the University of Cincinnati and MDS Analytical Technologies have used mass spectrometry to develop a high-throughput screening method for drug discovery they say can be more precise and cost-effective than existing techniques.
The technique is based on a MALDI triple-quadrupole platform and exploits the selective multiple-reaction
More bioscreening news...
22.10.2009 Scripps Research scientists awarded $3.9 million grant to develop new compound screening platform
Bicoastal effort could help revolutionize the search for new therapies
La Jolla, CA, and Jupiter, FL, October 5, 2009 –A pair of scientists from The Scripps Research Institute, one on each coast, has been awarded a five-year $3.9 million grant from the National Institutes of Health (NIH) to develop a new technology to accelerate the search
More bioscreening news...
22.10.2009 BioServe to Test for Swine Flu in India
Beltsville, MD; and Hyderbad, AP, India, October 21, 2009 – BioServe, a leading provider of clinical bio-samples and research services, today announced that it has been selected by the Government of the State of Andhra Pradesh in India and The Institute of Preventive Medicine (IPM) Hyderabad as one of two private diagnostic centers to test
More bioscreening news...
new | june 2010 | october 2009 | may 2009 | january 2009 | october 2008 | april 2008 | january 2008 | october 2007 | september 2007 | august 2007 | march 2007 | february 2007 | january 2007 | december 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004 | october 2004 | september 2004 | august 2004 | july 2004 | june 2004 | may 2004 | april 2004 | march 2004 | february 2004 | january 2004 | december 2004 | november 2003 | october 2003 | september 2003 | august 2003 | july 2003 | june 2003 | may 2003
|
